Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus vs MMF in Heart Transplant
NCT00150046Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2004
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of everolimus in heart transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Renal function (Creatinine Clearance) at 12 months. Started Dec 2004; status: completed.
02
Drugs
everolimus
03
Conditions
heart transplant rejection
Beyond the preview
Go deeper on NCT00150046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00150046.